Adaptive Biotech

There’s still time to register for our March 18 webinar ⏰ Learn how immunosequencing and large scale immune data drive smarter R&D decisions—from MoA validation to PK/PD and TCR signal detection. 👉 Register: adaptivebio.tech/dc215c

This #IWD2026, Sr. Dir. R&D Katie Husske reminds us, “each of us has something valuable to contribute—whether it’s our expertise, our time, or simply a willingness to listen.” #GiveToGain #BeAdaptive

March is Myeloma Action Month. 🩸 Taking action starts with awareness. Understanding what remains can change what comes next. #MyelomaActionMonth #MoreThanMyeloma

Last week, we came together to celebrate #BlackHistoryMonth and welcome the #YearoftheHorse with shared traditions, a festive raffle and bake sale. We proudly raised funds to support the William Grose Center for Cultural Innovation in Seattle’s Central District.

New Adaptive research, featured in @DrugDiscovNews, shows how T-cell receptor sequencing can identify shared, celiac-associated immune signatures in blood—highlighting the potential for a noninvasive approach to studying and monitoring celiac disease.🔗 adaptivebio.tech/fth

Join our 3/18 webinar covering our immunosequencing technologies and large-scale database that inform actionable R&D decisions to accelerate the development of immune-modulating therapies. Register: adaptivebio.tech/dc215c

This #BlackHistoryMonth, we recognize Nyabuom Chuol, Senior Clinical Services Specialist, for her leadership within our Black Adapter Network #ERG. Nyabuom strengthens connections, advances inclusion, and helps foster a culture of belonging across our organization. #BeAdaptive

Excited to join experts in HCT, cellular and gene therapy at the 2026 Tandem Meetings of @ASTCT and @CIBMTR! Stop by Booth #108. #Tandem26

We’re proud to be recognized with the Human Rights Campaign Foundation's Equity 100 Award for our commitment to equity and inclusion in the workplace. Read more: adaptivebio.tech/o5h

FDA released draft guidance on the use of MRD as an endpoint to support accelerated approval in multiple myeloma, consistent w/ the 2024 ODAC recommendation. This positive step forward may help bring new therapies to patients and providers more quickly. adaptivebio.tech/ema

We’re excited to kick off the year at #JPM26. CEO Chad Robins will present on Monday, January 12 at 4:30 p.m. PT / 7:30 p.m. ET. A live and archived webcast of the event will be available in the investors section of our website. adaptivebio.tech/qf0

As we close out the year, we’re grateful for the curiosity, collaboration, and innovation that drive our work—and the colleagues and partners who make it possible. #BeAdaptive #HappyNewYear

We’ve now reached 100,000 patients tested with clonoSEQ®. Grateful to the patients and clinicians who trust us in their care journey. Learn more: clonoSEQ.com

Adaptive has entered into two licensing agreements with @Pfizer, leveraging our immune medicine platform and precision immunology data to inform the potential development of immune-based therapeutic products. Learn more: adaptivebio.tech/6qq

Learn more about how clonoSEQ is being utilized to guide clinical decisions at key points in care across the latest #ASH25 research: adaptivebio.tech/q5p

Grateful for the teams powering our work at Adaptive—today and every day. Wishing you all a warm and restful Thanksgiving. #Thanksgiving #BeAdaptive

Nearly 90 abstracts featuring clonoSEQ® MRD testing will be presented at #ASH25, reflecting the growing adoption of MRD. Read the full press release here: adaptivebio.tech/2v3 #clonoSEQ #MRD #BloodCancer

Celebrating 250 years of the U.S. Marine Corps and honoring all who serve. #USMC250 #VeteransDay

Behind every patient is someone walking beside them through uncertainty, treatment, and recovery. Thank you to all caregivers. Watch Anne & Jim’s story: adaptivebiotech.wistia.com/medias/k8kxzym… #NationalFamilyCaregiversMonth #CancerJourney #CaregiverStrong

Heading to #SITC2025? Don’t miss our Friday lunch symposium on 11/7 at 12:30 p.m. Adaptive's Stephanie Bien and David Schaer, PhD from Bayer will discuss how large-scale immune repertoire data is driving smarter decisions in immune-modulating therapy development.